Parathyroid hormone in the treatment of osteoporosis

BioDrugs

Volumn 15, Issue 11, 2001, Pages 721-728

  Fujita, Takuo ^a,b  

^a Katsuragi Hospital   (Japan)

^b Katsuragi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ARZOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; ESTROGEN; GROWTH HORMONE; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-31]; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[1-36]; PARATHYROID HORMONE[1-38]; PROSTAGLANDIN; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; BONE MASS; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; HUMAN; HYPERPARATHYROIDISM; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TRABECULAR BONE;

EID: 0035212976     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115110-00003     Document Type: Review

References (52)

1. Cooper C, Melton LJ III. Magnitude and impact of osteoporosis. In: Marcus R, FeldmanD, Kelsey J, editors. Osteoporosis. San Diego: Academic Press, 1995: 419-34
2. Dempster DW, Cosman F, Parsien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14:690-709
3. Reeve J, Hesp R, Williams D, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976; 1: 1035-8
4. Hodsman AB, Fraher LJ. Biochemical response to synthetic human parathyroid hormone (1-38) and calcitonin in osteoporotic subjects. Bone Miner 1990; 9: 137-52
5. Stewart AF. PTHrP (1-36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone 1996; 19: 303-6
6. Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1, 25-dihydroxyvitamin D. J Bone Miner Res 1986; 1: 377-81
7. Whitfield J, Morley P, Willick G. The parathyroid hormone, its fragments and analogues; potent bone-builders for treating osteoporosis. Expert Opin Invest Drugs 2000; 9: 1293-315
8. Bradbeer JN. Arlot ME, Meunier PJ, et al. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 1992; 37: 282-9
9. Friedman PA, Gesek FA, Morley P, et al. Cell-specific signaling and structure-activity relations of parathyroid hormone analogues in mouse kidney cells. Endocrinology 1999; 140: 301-9
10. Reeve J, Meunier P, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trial. BMJ 1980: 280: 1340-4
11. Reeve J. Davies UM, Hesp R, et al. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ 1990; 301: 314-8
12. Neer RM, Slovik D, Doppelt S. The use of parathyroid hormone plus 1,25-dihydroxyvitamin D to increase trabecular bone in osteoporotic men and postmenopausal women. In: Christiansen C, Johansen JS, Ras BJ, editors. Osteoporosis. Copenhagen: Osteopress, 1987: 829-35
13. Neer RM, Slovik DM, Daly N, et al. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 1993; 1: S204-5
14. Hesch RD, Busch U, Prokop M, et al. Increase of vertebral density by combination therapy with pulsatile 1 -38 h PTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989; 44: 176-80
15. Hesch RD, Heck J, Auf'mKolk B, et al. First clinical observations with hPTH( 1 -38), a more potent human parathyroid hormone peptide. Horm Metab Res 1984; 16: 559-60
16. Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone-(l31)NH2 and hPTH (1-34) in healthy humans. J Clin Endocrinol Metab 1999; 84: 2739-43
17. Mohan S, Kutilek S, Zhang C, et al. Comparison of bone formation responses to parathyroid hormone ( 1 -34), ( 1 -31 ) and (2-34) in mice. Bone 2000; 27: 471-8
18. Whitfield JF, Morley P, Willick G, et al. Cyclization by a specific lactam increases the ability of human parathyroid hormone hPTH-(l-31)NH2 to stimulate bone growth in ovariectomized rats. J Bone Miner Res 1997; 12: 1246-52
19. Plotkin H, Gundberg C, Mitnick M, et al. Dissociation of bone formation from résorption with human parathyroid hormonerelated peptide-(l-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 1998; 83: 2786-91
20. Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-5
21. Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(l-34): a randomized controlled trial. JAMA 1998; 280: 1067-73
22. FujitaT, Inoue T, Morii H, et al. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999; 9: 296-306
23. Parisien M, Dempster DW, Shane E, et al. Histomorphometric analysis of bone in primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. Basic and clinical concepts. 2nd ed. San Diego: Academic Press. 2001:423-36
24. Tarn CS, Heersche JN, Murray TM, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982: 110: 506-12
25. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men. Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-76
26. Schwielen HR. Groen EW, Sollie FA, et al. Single dose subcutaneous administration of recombinant human parathyroid hormone, rhPTH(l-84) in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997; 61: 360-76
27. Lindsay R, Hodsman A. Genant HK. A randomized controlled multicenter study of 1-84 h PTH for treatment of postmenopausal osteoporosis. Bone 1998; 23: S175
28. Neer R, Slovik DM, Daily N. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. In: Christiansen C, Overgaard K, editors. Osteoporosis. Copenhagen: Osteopress. 1991: 1314-17
29. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997; 82: 620-8
30. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-33
31. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
32. Haguenauer D, Welch V, Shea B, et al. Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2000; (4): CD002825
33. Atkins D, Zanelli JM, Peacock M, et al. The effect of oestrogens on the response of bone to parathyroid hormone in vitro. J Endocrinol 1972; 54: 107-17
34. Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(l-34): kinetics and biochemical responses in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993; 77:1535-9
35. Roe EB, Sanchez SD, Del Puerto GA. Parathyroid hormone 1-34 (PTH1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis. J Bone Miner Res 1999; 14:S137
36. Cann CE, Roe EB, Sanchez SD, et al. PTH effects in the femur. Envelope-specific responses by 3DQCT in postmenopausal women. J Bone Miner Res 1999; 14: S137
37. Roe EB, Sanchez SD, Cann CE, et al. PTH-induced increases of bone density are preserved with estrogens: results from a follow-up year in postmenopausal osteoporosis. J Bone Miner Res 2000; 15:5193
38. Hodsman AB, Drost D, Fraher LG, et al. The action of a raloxifene analog (LY117018) allows for reduced PTH ( 1 -34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res 1999; 14: 675-9
39. Sato M, Zeng GQ, Roeley E, et al. LY 353381/HCI : an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(l-34). Endocrinology 1998; 139: 4642-51
40. Burr DB, Hirano T, Turner CH, et al. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humérus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001; 16: 157-65
41. Hodsman AB, Steer BM, Fraher LJ, et al. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone ( 1 -38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991; 14: 67-83
42. Cosman F. Nieves J, Woelfert L. et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13: 1051-5
43. Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and résorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 1993; 91:113848
44. Rittersmith RS, Bolognese M, Ettinger MP. et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol 2000; 85: 2129-34
45. Hodsman AB, Fraher L, Adachi J. A clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone in the treatment of postmenopausal osteoporosis. J Bone Miner Res 1995; 10: S200
46. Takano Y. Tanizawa T, KashibaT, et al. Maintaining bone mass by bisphosphonate incadronate disodium (YM 175) sequential treatment after discontinuation of intermittent human parathyroid hormone ( 1 -34) administration in ovariectomized rats. J Bone Miner Res 1996; 11: 169-77
47. Mashiba T, Tanizawa T, Takano Y, et al. A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1-34) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats. Bone 1995; 17: 273S-8S
48. Wronski TJ, Yen CF, Scott KS. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 1991 ; 6: 387-94
49. Greenspan SL, Holland S, Maitlamd-Ramsey L, et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement of bone mineral density accompanying alendronate therapy. Proc Ass Am Physicians 1996; 108: 230-8
50. Hock JM. Fonseca J. Anabolic effect of human synthetic parathyroid hormone-(l-34) depends on growth hormone. Endocrinology 1990; 127: 1804-10
51. Anderssen TT, Oxlund H. The influence of combined parathyroid hormone and growth hormone treatment on cortical bone in aged ovariectomized rats. J Bone Miner Res 2000; 15: 2266-75
52. Opas EE, Gentile MA, Rossert JA, et al. Parathyroid hormone and prostaglandin £2 preferentially increase luciferase levels in bone of mice harboring a luciferase transgene controlled by elements of the Pro-al(I) collagen promoter. Bone 2000; 26: 27-32